Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Other Non-Current Liabilities (2013 - 2025)

Grifols' (GIFLF) quarterly Other Non-Current Liabilities came in at $3.5 million in Q4 2025, up 226.8% on a YoY basis from $1.1 million in Q4 2024, and up 226.8% quarter-over-quarter from $1.1 million in Q4 2024.

Analysis

Grifols (GIFLF) Other Non-Current Liabilities (2013 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Other Non-Current Liabilities for 13 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 226.8% year-over-year to $3.5 million; the trailing twelve-month figure through Dec 2025 stood at $3.5 million (up 226.8% YoY), and the FY2025 full-year result was $3.4 million, up 217.19% from the prior year.
  • Other Non-Current Liabilities grew to $3.5 million in Q4 2025 per GIFLF's latest filing, from $1.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $380.9 million in Q4 2021 and bottomed at -$3.8 billion in Q4 2023.
  • Historically, Other Non-Current Liabilities has averaged -$679.1 million across 5 years, with a median of $3.5 million in 2025.
  • The sharpest annual moves came in 2021 and 2023: Other Non-Current Liabilities soared 1849.27% in 2021, then plunged 24905.17% in 2023.
  • Over 5 years, Other Non-Current Liabilities stood at $380.9 million in 2021, then sank by 95.98% to $15.3 million in 2022, then sank by 24905.17% to -$3.8 billion in 2023, then jumped by 100.03% to $1.1 million in 2024, then surged by 226.8% to $3.5 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.5 million, $1.1 million, and -$3.8 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 3.49 Mn
Dec 31, 2024 1.07 Mn
Dec 31, 2023 -3.80 Bn
Dec 31, 2022 15.30 Mn
Dec 31, 2021 380.94 Mn
Dec 31, 2020 19.54 Mn
Sep 30, 2020 661.48 Mn
Mar 31, 2020 543.55 Mn
Dec 31, 2019 1.09 Mn
Sep 30, 2019 497.08 Mn
Dec 31, 2018 1.48 Mn
Sep 30, 2018 500.18 Mn
Jun 30, 2018 2.44 Mn
Mar 31, 2018 529.17 Mn
Dec 31, 2017 478.62 Mn
Mar 31, 2016 3.31 Mn
Dec 31, 2015 8.08 Mn
Dec 31, 2014 -5.97 Bn
Dec 31, 2013 618.06 Mn